Adiponectin and cardiovascular risk factors in relation with glycemic control in type 2 diabetics

Aniebetabasi S. Obot, Chinyere A. O Usoro, Augusta C. Nsonwu-Anyanwu, Edmund R. Egbe, John U. Ekott, Anthony J. Usoro


Background: Adiponectin has been associated with insulin resistance and dyslipidemia in Type 2 diabetes, though the mechanism of association is still uncertain. The adiponectin levels and lipid profile in relation to glycemic control were investigated in type 2 diabetics.

Methods: Forty two diabetic subjects (35-64 years) and 33 age-matched non-diabetic subjects were recruited into this case control study. Socio-demographic characteristics, anthropometric indices and blood pressure were obtained. Total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein, (HDL), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) were estimated using colorimetric methods, atherogenic index (AI) was calculated, while serum adiponectin was determined by ELISA method.

Results: Adiponectin levels of type 2 diabetics were not significantly different from the non-diabetics studied (p>0.05).  Higher TG levels were observed in diabetics with poor glycemic control compared with those with good glycemic control (p<0.05). Hypertensive diabetics have higher TC and lower HDL-C levels compared with non hypertensive diabetics (p<0.05). Adiponectin correlated positively with HDL-C (r = 0.739, p = 0.01) and negatively with AI (r = -0.539, p = 0.001) only in the non diabetic group. No significant differences were observed in the adiponectin levels in relation with gender, duration of diabetes and glycemic state (p>0.05).

Conclusion: Type 2 diabetics do not have lower adiponectin levels. Gender, duration of diabetes and glycemic control does not seem to exert any influence on adiponectin levels in type 2 diabetes. Adiponectin may be associated with reduced risk of atherosclerosis through its effects on HDL cholesterol metabolism.



Type 2 diabetes, Adiponectin, Lipid profile, Glycemic control

Full Text:



Nemet, D, Ping W, Tohru F, Yuji M, Sachiyo T, Laszlo E, et al. Relationships among adiponectin and other adipose cytokines, body composition, and fasting insulin in lower socio-economic middle school children. American Physiological Society’s (APS) Abstract 2002.

Schulze M. B, Shai I, Rimm E. B, Li T, Rifai N, Hu F. B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005: 54: 534–539.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat - derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001;7(8):941-6.

Kubota, N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of a diponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002: 24 (epub ahead of print).

Berg A.H, Combs T. P, Du X, Brownlee M, Scherer P. E.The adipocyte - secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 2001;7(8):947-55.

Umar H. and Adam J. M. F. Low adiponectin levels and the risk of type 2 diabetes mellitus. The Indonesian Journal of Medical Science 2009: 2 (1):56-60.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000: 20:1595-1599.

Buscemi S, Verga S, Cottone S. Glycaemic variability and inflammation in subjects with metabolic syndrome. Acta Diabetes 2009; 46(1): 55-61.

Schulze M. B, Rimm E. B, Shai I, Rifai N, Hu F. B. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004: 27(7):1680-7.

Mantzoros C. S, Li T, Manson, J. E, Meigs, J. B, Hu F. B. Circulating Adiponectin Levels Are Associated with Better Glycemic Control, More Favorable Lipid Profile, and Reduced Inflammation in Women with Type 2 Diabetes. J. Clin Endocrinol Metab 2005: 90: 4542–4548.

Friedewald W. T, Levy R.I, Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972:18:499-502.

Ljubic S, Boras J, Jazbec A, Lovrencic M. V, Vidjak V, Erzen D.J et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32 (4): E271-E279.

Sharma P. K., Bhansali A., Sialy R., Malhotra S, Pandhi P. Effects of Pioglitazone and Metformin on Plasma Adiponectin in Newly Detected Type 2 Diabetes Mellitus. Clin Endocrinol. 2006; 65(6): 722-728.

Tsunekawa T., Honyashi T., Suzuki Y., Matsui–Hairai H., Kano H., Fukatsu A, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimeride in elderly type 2 diabetic subjects. Diabetes Care 2003: 26: 285–286.

Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I. & Matsuzawa, Y. (2001) PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001: 50: 2094-2099.

Araki T., Emoto M., Konishi T., Ikuno Y., Lee E., Teramura M, et al. Glimepiride increases high density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism Clinical and Experimental 2009: 58: 143-148.

Kanda Y., Matsuda M., Tawaramoto K., Kawasaki F., Hashiramoto M., Matsuki M. Kaku K. 2008. Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: Implication of different mechanism from pioglitazone. Diabetes Research and Clinical Practice 2008: 18 (1): 13-18.

Abdelgadir M, Karlsson A. F, Berglund L, Berne C. Low serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 2013: 5:15-20.

Gligor R, Puşchiţă M, Zdremţan D, Crîsnic I. Relationship between adiponectin and certain metabolic parameters in diabetic and cardiovascular disease patients. Proc. Rom. Acad., Series B 2012: 14: 101-107.

El-Nuweihy A. M, El-Melegy N. T, Ameen N. F. Radwan E. M. Role of adiponectin in patients with non-insulin dependent diabetes mellitus. Bull. Pharm. Sci., Assiut University 2010: 33 (2): 107-120.

Lapolla, A., Molin, L, Traldi P. Protein Glycation in Diabetes as Determined by Mass Spectrometry. International Journal of Endocrinology 2013:

Stanaway S. E., Gill G.V. Protein glycosylation in diabetes mellitus, biochemical and clinical considerations. Practical Diabetes International 2000: 17: 21-25.

Al-Mukhtar S. B., Fadhil N. N., Hanna B. E. Serum lipid profile in subjects with type 2 diabetes mellitus and hypertension in relation to metabolic syndrome: a case control study. Duhok Med J 2012; 6(2): 29-44.

Ginsberg H.N. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996: 45 (3):827–530.

Del Pilar S. M, Goldberg R. B. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2005: 34: 1–25.

Adiels M, Westerbacka J, Soro-Paavonen A, Häkkinen AM, Vehkavaara S, Caslake M. J. Acute suppression of VLDL secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia. 2007;50:2356–65.

Sen S, Sinha S, Gupta K.K. Comparative evaluation of effects of combined oral anti-diabetic drugs (sulfonylurea plus pioglitazone and sulfonylurea plus metformin) over lipid parameters in type 2 diabetic patients. International Journal of Basic & Clinical Pharmacology 2013: 2 (3) : 257-263.

Tuñón J., Martín-Ventura J. L., Blanco-Colio L. M.,Tarín N, Egido J. Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vascular Health and Risk Management 2007:3(4): 521–526.

Prabodh S., Sripad D. V., Chowdary N. V. S., Shekhar R. Hypertension and dyslipidemia in type 2 diabetes mellitus patients of guntur and krishna districts in andhra pradesh, india. National Journal of Laboratoy Medicine 2012: 1 (1): 7-10.

Sowers J R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286(5):H1, 597-602.

Adler A. I, Stratton I. M, Neil A. W, Yudkin J. S, Matthews D. R, Cull C. A. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Medical Journal 2000; 321(7,258):412-419.

Hsu C. H., Liao Y. L., Lin S. C, Chou P. Adiponectin Level Predicts HDL-Cholesterol Level in Type 2 Diabetes. Atherosclerosis & Thrombosis Journal 2012;5:1-5.

Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004: 68(11):975-981.

Hao W, Dao-Quan P. New insights into the mechanism of low high density lipoprotein cholesterol in obesity. Lipids in Health and Disease 2011;10:176-186.

Mojtaba E., Anoosh E., Shahram S, Reza I. Adiponectin in relation cardiovascular risk factors in diabetic. Annals of Biological Research 2011;2(6):349-355

Jiang R, Schulze M. B, Li T, Rifai N, Stampfer M. J, Rimm E. B. Non HDL cholesterol and apolipoprotein B predicts cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27(8):1991-1997.

Bidulescu A, Liu J, Hickson DA, Hairston KG, Fox ER, Arnett DK, et al. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. BMC Cardiovascular Disorders 2013: 13:9-17.

Esteghamati A, Mousavizadeh M, Noshad S, Zandieh A, Zarei H, Nakhjavani M. Gender-dependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: a randomized clinical trial. Horm Metab Res. 2013: 45(4):319-25.

Goodarzi M.T, Babaahmadi R. H, Kadkhodaei E. M, Haddadinezhad S. Relationship of serum adiponectin with blood lipids, HbA1c, and hs CRP in type II diabetic postmenopausal women. J Clin Lab Anal. 2007; 21(3):197-200.

Blaslov K, Bulum K, Zibar K, Vrhovac L. D. Relationship between Adiponectin Level, Insulin Sensitivity, and Metabolic Syndrome in Type 1 Diabetic Patients. International Journal of Endocrinology.2013: